Aquestive Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 1 month.
- Its last 8 Sell calls were actually followed by a +36% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -30.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 23.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 58.3% | Better than 73% |
| Operating margin | -159.5% | Better than 6% |
| Net margin | -188.1% | Better than 5% |
| Return on equity | -3,347.4% | Better than 0% |
| Return on invested capital | -107.7% | Better than 2% |
Momentum D+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -25.8% | Better than 22% |
| 6-month return | -16.0% | Better than 31% |
| 12-month return (ex latest month) | -30.1% | Better than 9% |
| Distance below 52-week high | 48.6% | Better than 20% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.1x | Better than 74% |
| Debt to assets | 26.5% | Better than 46% |
| Interest coverage | -3.9x | Better than 18% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 167.3% | Better than 92% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 3.71
- Open
- 3.62
- Day range
- 3.41 - 3.65
- Avg price
- 3.51
- Volume
- 3.36M
- Turnover
- 11.78M
- Turnover ratei
- 2.97%
- Volume ratioi
- 1.48
- Amplitudei
- 6.59%
- 52-week rangei
- 2.93 - 6.74
Valuation
- P/Ei
- -4.44
- P/E (TTM)i
- -5.32
- P/Bi
- -6.15
- EPSi
- -0.78
- Book value / shi
- -0.56
- Net profit
- -98.04M
- Net assets
- -70.76M
Share structure
- Market cap
- 434.88M
- Float capi
- 391.62M
- Shares out
- 125.69M
- Float sharesi
- 113.19M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-07-25
48.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.50M net over the window
Short interest
- Shares short
- 29.32M
- % of floati
- 23.36%
- Days to coveri
- 13.24
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Aquestive Therapeutics (AQST)?
Aquestive Therapeutics last traded at 3.46. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Aquestive Therapeutics's market cap?
About 434.88M.
What is the P/E ratio of Aquestive Therapeutics?
The trailing twelve-month P/E is -5.32. The Valuation tab shows it against the stock's own five-year range.
Does Aquestive Therapeutics pay a dividend?
Aquestive Therapeutics does not currently pay a regular dividend.
Is Aquestive Therapeutics a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 9.25, which implies 167.3% upside from the current price. This is not investment advice.
What is Aquestive Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Aquestive Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Aquestive Therapeutics discussion 0 comments